# Dianthus Therapeutics Inc. (DNTH) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $108.10, market value $6.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Dianthus Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2969.8×**. Each dollar of revenue is priced at 2969.8×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 5.1×**. The shares trade at 5.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Return on equity: -32.9%**. Return on equity is negative because earnings are negative.
- **Return on assets: -30.6%**. Each dollar of assets produces -30.6% of profit.

## Growth
- **Revenue growth (1 yr): -67.3%**. Revenue fell 67.3% over the last year.
- **EPS growth (1 yr): -64.7%**. Earnings per share fell 64.7%, roughly in step with revenue.

## Financial health
- **Current ratio: 13.32** (quick 13.32). Current assets cover the next year's liabilities 13.32 times.
- **Altman Z-score: 97.74**. A Z-score of 97.74 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Dianthus Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover Dianthus Therapeutics Inc.; the consensus is strong_buy, with an average price target of $137.62 (+27% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 338.4%** (YTD 162.3%, 3-mo 34.3%). The shares are up 338.4% over twelve months including dividends.
- **From 52-week high: -8.3%** (257.9% above the low). Trading 8% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 0.92** (volatility 65%). Beta of 0.92 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DNTH · Page: https://foliofundamentals.com/stocks/dnth

Not investment advice.